AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.4% – Should You Sell?

AnaptysBio, Inc. (NASDAQ:ANAB) fell 5.4% during trading on Monday . The company traded as low as $20.51 and last traded at $20.51. 10,002 shares changed hands during trading, a decline of 97% from the average session volume of 342,041 shares. The stock had previously closed at $21.68.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ANAB. Guggenheim raised their price target on AnaptysBio from $75.00 to $90.00 and gave the company a “buy” rating in a report on Monday, October 21st. JPMorgan Chase & Co. raised their target price on AnaptysBio from $69.00 to $75.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. UBS Group upped their price target on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Truist Financial increased their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of AnaptysBio in a research note on Thursday. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.73.

AnaptysBio Stock Performance

The company has a 50-day moving average price of $34.28 and a 200-day moving average price of $29.94. The firm has a market capitalization of $552.71 million, a P/E ratio of -3.15 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.82). The company had revenue of $10.97 million for the quarter, compared to the consensus estimate of $25.85 million. AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. Equities analysts predict that AnaptysBio, Inc. will post -6.84 EPS for the current year.

Insider Activity at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the company’s stock in a transaction on Wednesday, August 14th. The shares were purchased at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the purchase, the insider now directly owns 7,794,996 shares of the company’s stock, valued at $284,517,354. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Dennis Mulroy sold 12,220 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the transaction, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at $189,333.04. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock worth $892,936 in the last ninety days. Company insiders own 33.70% of the company’s stock.

Institutional Trading of AnaptysBio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Values First Advisors Inc. bought a new position in shares of AnaptysBio in the third quarter valued at $49,000. nVerses Capital LLC lifted its stake in AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 1,400 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of AnaptysBio in the 1st quarter valued at about $38,000. Headlands Technologies LLC increased its stake in shares of AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 2,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 2,600 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.